Today, Sept.1st, the FDA announced its findings regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.
Read Article
Dr. Jack Cush is joined by Drs.
Read Article
Statement from ACR President David Karp, MD, PhD:
Read Article
As many of you are aware, I have written and spoken on COVID-19 extensively over these past 20 months, and just last month wrote about the dangers of the delta variant. In July, things took an unexpected turn when I developed a breakthrough infection with the delta variant.
Read Article
This is the #1 question I get from new consults: “How did I get arthritis?”
But as aching patients ask this question, they are really thinking these joint complaints must be due to:
Read Article
Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.
Read Article
Dr Jack Cush reviews the news, journal articles and FDA warnings from the past week on RheumNow.com
Read Article
Tumor necrosis factor inhibitors (TNFi) are frequently used first line in rheumatoid arthritis (RA) patients; and a new analysis shows that repeat use of TNFi dominates over the use of non-TNFi biologics when the initial TNFi therapy has failed.
Read Article
Who is the greatest rheumatologist? What makes for a great rheum?
Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring?
Read Article
Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was protective
Read Article
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.
Read Article
Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT) had l
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.
Read Article
Dr. Jack Cush reviews the news and journal reports and takes cases and questions from rheumatologists.
Read Article
Wow! I hope you read part I of yesterday's “Greatest Rheumatologist” article. So many big names and yet, other names and stories that were equally inspirational.
If you read the comments of the part I article you can clearly see several themes emerge.
Read Article
A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype.
Read Article
Rheumatology has become a highly competitive field, attracting the brightest and the best of internists, aspiring to careers in rheumatology. The skills of a rheumatologist include: curiosity, cognitive reasoning, diagnostic acumen, and love for exploration; with a degree of skepticism.
Read Article
Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.
Read Article
A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.
Read Article
